Siren, L.L.C. Moon Lake Immunotherapeutics Transaction History
Siren, L.L.C.
- $1.93 Trillion
- Q2 2025
A detailed history of Siren, L.L.C. transactions in Moon Lake Immunotherapeutics stock. As of the latest transaction made, Siren, L.L.C. holds 508,267 shares of MLTX stock, worth $28.1 Million. This represents 1.24% of its overall portfolio holdings.
Number of Shares
508,267Holding current value
$28.1 Million% of portfolio
1.24%Shares
1 transactions
Others Institutions Holding MLTX
# of Institutions
157Shares Held
54.8MCall Options Held
799KPut Options Held
661K-
Bvf Inc San Francisco, CA19.8MShares$1.09 Billion36.63% of portfolio
-
Cormorant Asset Management, LP Boston, MA8.49MShares$470 Million40.43% of portfolio
-
Avoro Capital Advisors LLC New York, NY4.15MShares$230 Million3.57% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD2.61MShares$145 Million0.01% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il1.67MShares$92.7 Million0.01% of portfolio
About MoonLake Immunotherapeutics
- Ticker MLTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 36,925,600
- Market Cap $2.04B
- Description
- MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or rad...